Efficacy of AS04-Adjuvanted Vaccine Against Human Papillomavirus (HPV) Types 16 and 18 in Clearing Incident HPV Infections: Pooled Analysis of Data From the Costa Rica Vaccine Trial and the PATRICIA Study.
Joseph E TotaFrank StruyfAllan HildesheimPaula GonzalezMartin RyserRolando HerreroJohn SchusslerNaveen KarkadaAna Cecilia RodriguezNicolas FolschweillerCarolina PorrasMark SchiffmanJohn T SchillerWim QuintAimée R KreimerMatti LehtinenCosette M WheelerJoshua N SampsonPublished in: The Journal of infectious diseases (2022)
Clinical trial data and real-world evidence suggest that the AS04-adjuvanted vaccine targeting human papillomavirus types 16 and 18 (AS04-HPV-16/18) vaccine provides nearly 90% protection against cervical intraepithelial neoplasia grade 3 or higher irrespective of type, among women vaccinated before sexual debut. This high efficacy is not fully explained by cross-protection. Although AS04-HPV-16/18 vaccination does not affect clearance of prevalent infections, it may accelerate clearance of newly acquired infections. We pooled data from 2 large-scale randomized controlled trials to evaluate efficacy of the AS04-HPV-16/18 vaccine against clearance of nontargeted incident infections. Results of our analysis do not suggest an effect in expediting clearance of incident infections.
Keyphrases
- high grade
- cervical cancer screening
- clinical trial
- cardiovascular disease
- electronic health record
- phase iii
- randomized controlled trial
- big data
- study protocol
- systematic review
- metabolic syndrome
- phase ii
- pregnant women
- mass spectrometry
- data analysis
- adipose tissue
- insulin resistance
- cancer therapy
- skeletal muscle
- tandem mass spectrometry